208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014

Neuromuscular Disorders

Volumn 25, Issue 8, 2015, Pages 674-678

  Schoser, Benedikt ^a   Laforêt, Pascal ^b   Kruijshaar, Michelle E ^c   Toscano, Antonio ^d   van Doorn, Pieter A ^c   van der Ploeg, Ans T ^c   Angelini, Corrado ^e   van der Beek, Nadine A M E ^e   Van den Bergh, Peter ^e   Broomfield, Alexander ^f   Desnuelle, Claude ^e   Hahn, Andreas ^e   Lachmann, Robin ^g   Mengel, Eugen ^e   Mongini, Tiziana ^e   Müller Felber, Wolfgang ^e   Padberg, George ^h   Parenti, Giancarlo ^e   Pascual, Ignacio Pascual ^e   Pijnappel, W W M Pim ^e   Roberts, Mark ^f   Talim, Beril ^e   Treur, Wilma ^e   Vissing, John ^e   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MESSINA   (Italy)

^e ENMC ^*  (Denmark)

^f Manchester   (United Kingdom)

^g University London   (United Kingdom)

^h ENMC   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

6 MINUTE WALK TEST; ARTICLE; BELGIUM; CLINICAL ASSESSMENT; CONSENSUS DEVELOPMENT; DENMARK; DYNAMOMETRY; ENZYME REPLACEMENT; EVIDENCE BASED MEDICINE; FATIGUE SEVERITY SCALE; FOUR TIMED TEST; FRANCE; FUNCTIONAL ASSESSMENT; GERMANY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; ITALY; LUNG FUNCTION TEST; MEDICAL INFORMATION SYSTEM; MUSCLE FUNCTION; MUSCLE STRENGTH; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SPAIN; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; ENZYMOLOGY; GLYCOGEN STORAGE DISEASE TYPE II; INFORMATION DISSEMINATION; TREATMENT OUTCOME; TRENDS;

ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFORMATION DISSEMINATION; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84937643589     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2015.04.006     Document Type: Article

References (22)

1. Amalfitano A., Bengur A.R., Morse R.P., et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001, 3(2):132-138.
2. Kishnani P.S., Corzo D., Nicolino M., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68(2):99-109.
3. Van den Hout H., Reuser A.J., Vulto A.G., et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000, 356(9227):397-398.
4. Van den Hout J.M., Kamphoven J.H., Winkel L.P., et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004, 113(5):e448-57.
5. de Vries J.M., van der Beek N.A., Hop W.C., et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 2012, 7:73.
6. Gungor D., Kruijshaar M.E., Plug I., et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013, 8:49.
7. Toscano A., Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 2013, 260(4):951-959.
8. Barba-Romero M.A., Barrot E., Bautista-Lorite J., et al. Clinical guidelines for late-onset Pompe disease. Rev Neurol 2012, 54(8):497-507.
9. Bhengu L., Davidson A., du Toit P., et al. Diagnosis and management of Pompe disease. S Afr Med J 2014, 104(4):273-274.
10. Cupler E.J., Berger K.I., Leshner R.T., et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012, 45(3):319-333.
11. Dubrovskya A., Fulgenzib E., Amartinoc H., et al. Consenso argentino para el diagnóstico, seguimiento y tratamiento de la enfermedad de Pompe. Neurol Argent 2014, 6(2):96-113.
12. Hundsberger T., Rohrbach M., Kern L., Rosler K.M. Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol 2013, 260(9):2279-2285.
13. Llerena J.C., Horovitz D.M., Marie S.K., et al. The Brazilian consensus on the management of Pompe disease. J Pediatr 2009, 155(Suppl. 4):S47-56.
14. Schuller A., Kornblum C., Deschauer M., et al. [Diagnosis and therapy of late onset Pompe disease] Diagnose und therapie des late-onset-morbus-Pompe. Nervenarzt 2013, 84(12):1467-1472.
15. Moniteur Belge/Belgisch Staatsblad. 19-08-2011: Brussels. 47840-47846, 2011.
16. Deegan P., Cox T.M., Waldek S., Lachmann R., Ramaswami U., Jessop E. Guidelines for the investigation and management of late onset acid maltase deficiency (type II glycogen storage disease/Pompe disease) 2015, in preparation.
17. Medical Research Council Aids to examination of the peripheral nervous system 1976, Memorandum no. 45. Her Majesty's Stationary Office: London.
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111-117.
19. American Thoracic Society/European Respiratory Society ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002, 166(4):518-624.
20. van der Beek N.A., Hagemans M.L., van der Ploeg A.T., van Doorn P.A., Merkies I.S. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord 2013, 23(3):256-264.
21. Hagemans M.L., van Schie S.P., Janssens A.C., et al. Fatigue: an important feature of late-onset Pompe disease. J Neurol 2007, 254(7):941-945.
22. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46(10):1121-1123.